Customized Adjuvant Chemo Falls Short in Early Lung Cancer

(MedPage Today) -- A pharmacogenomic-driven approach for adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) significantly reduced treatment-related toxicity but failed to improve survival in the international, phase III ITACA...